Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

por Achiron, Anat, Mandel, Mathilda, Dreyer-Alster, Sapir, Harari, Gil, Dolev, Mark, Menascu, Shay, Magalashvili, David, Flechter, Shlomo, Givon, Uri, Guber, Diana, Sonis, Polina, Zilkha-Falb, Rina, Gurevich, Michael
Publicado 2021

COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021

por Achiron, Anat, Dolev, Mark, Menascu, Shay, Zohar, Daniela-Noa, Dreyer-Alster, Sapir, Miron, Shmuel, Shirbint, Emanuel, Magalashvili, David, Flechter, Shlomo, Givon, Uri, Guber, Diana, Stern, Yael, Polliack, Michael, Falb, Rina, Gurevich, Michael
Publicado 2021

COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose

por Dreyer-Alster, Sapir, Menascu, Shay, Mandel, Mathilda, Shirbint, Emanuel, Magalashvili, David, Dolev, Mark, Flechter, Shlomo, Givon, Uri, Guber, Diana, Stern, Yael, Miron, Shmuel, Polliack, Michael, Falb, Rina, Sonis, Polina, Gurevich, Michael, Achiron, Anat
Publicado 2022